New Launch4 Nov 2025, 09:01 am
Glenmark Pharmaceuticals Inc., USA to Launch 8.4% Sodium Bicarbonate Injection USP
AI Summary
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. The product is bioequivalent and therapeutically equivalent to the reference listed drug of Abbott Laboratories Pharmaceutical Products Division. Glenmark will begin distribution in November 2025. The 8.4% Sodium Bicarbonate Injection market achieved annual sales of approximately $63.8 million as per IQVIA® sales data.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial.
- The product is bioequivalent and therapeutically equivalent to the reference listed drug of Abbott Laboratories Pharmaceutical Products Division.
- Glenmark will begin distribution in November 2025.
- The 8.4% Sodium Bicarbonate Injection market achieved annual sales of approximately $63.8 million as per IQVIA® sales data.